Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2024-06, Vol.26 (6), p.2446-2455
• Main Authors: Cariou, Bertrand, Linge, Jennifer, Neeland, Ian J., Dahlqvist Leinhard, Olof, Petersson, Mikael, Fernández Landó, Laura, Bray, Ross, Rodríguez, Ángel
• Format: Article
• Language: English
• Subjects: abdominal subcutaneous adipose tissue; Adipose tissue; Aged; Antidiabetics; Biobanks; Body fat; Body Fat Distribution; Body Mass Index; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; fat distribution pattern; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-2 Receptor; Humans; Hypoglycemic Agents - therapeutic use; Intra-Abdominal Fat - diagnostic imaging; Intra-Abdominal Fat - drug effects; liver fat; Magnetic Resonance Imaging; Male; Middle Aged; Tirzepatide; visceral adipose tissue
• ISSN: 1462-8902; 1463-1326; 1463-1326
• DOI: 10.1111/dom.15566

Aims To describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) in the SURPASS‐3 MRI substudy by comparison with sex‐ and BMI‐matched virtual control groups (VCGs) derived from the UK Biobank imaging study at baseline and Week 52. Methods For each study participant at baseline and Week 52 (N = 296), a VCG of ≥150 participants with the same sex and similar BMI was identified from the UK Biobank imaging study (N = 40 172). Average visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (aSAT) and liver fat (LF) levels and the observed standard deviations (SDs; standardized normal z‐scores: z‐VAT, z‐aSAT and z‐LF) were calculated based on the matched VCGs. Differences in z‐scores between baseline and Week 52 were calculated to describe potential shifts in fat distribution pattern independent of weight change. Results Baseline fat distribution patterns were similar across pooled tirzepatide (5, 10 and 15 mg) and insulin degludec (IDeg) arms. Compared with matched VCGs, SURPASS‐3 participants had higher baseline VAT (mean [SD] z‐VAT +0.42 [1.23]; p